ABBV-RGX-314 — Topline data
in 2026
Topline data from these trials are expected to be shared in 2026.Source filing
RGNX biotech catalysts & pipeline
REGENXBIO INC · Data as of 2026-09-08
Upcoming catalysts
clemidsogene lanparvovec — NDA/BLA submission
Q3 2026
REGENXBIO plans to resubmit the BLA in Q3 2026.Source filing
RGX-202 — NDA/BLA submission
this quarter
We remain focused on our Duchenne and retinal disease candidates, which utilize a different capsid and routes of administration, with near-term catalysts that are on track, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter.Source filing
surabgene lomparvovec — Topline data
Q4 2026
We remain focused on our Duchenne and retinal disease candidates, which utilize a different capsid and routes of administration, with near-term catalysts that are on track, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter.Source filing
surabgene lomparvovec — NDA/BLA submission
2027
Global regulatory submissions are expected in 2027.Source filing
RGX-202 — Regulatory decision
2H 2027
The Company is on track to initiate a BLA submission in Q3 2026 under the accelerated approval pathway, supporting potential approval in 2H 2027.Source filing